PDF(Pubmed)
Abstract：
Mesoporous silica nanoparticles (MSNPs) coated by chitosan (CS) were shown to be a proper candidate as a carrier for drug delivery purposes. However, choosing the suitable drug-containing complexes to be applied on MSNPs-CS is of much greater importance to evaluate the possible candidate for an efficient combination of cell viability, drug release kinetics, and atherosclerosis prevention. In this regard, this study concentrates on the synthesis and assessment of coated MSNPs-CS designed for drug delivery purposes. The MSNPs are coated with polyelectrolyte complexes (PEC) composed of CS and dextran sulfate (MSNPs-CS-DX), serving as a versatile drug carrier with favorable biological characteristics. CS-DX is applied to MSNPs without requiring complex or multi-step synthesis procedures. Rosuvastatin, a cholesterol-lowering medication, is chosen for its therapeutic relevance. Additionally, CS-DX is found to relatively impede the uptake of low-density lipoproteins (LDLs) by macrophages, enhancing their potential therapeutic utility. FTIR pattern, FESEM, and TEM images prove MSNPs-CS-DX formation. DLS measurement demonstrates the average particle size of 110 nm for MSNPs, with the combined thickness of CS and DX layers ranging from 10 to 15 nm. BET test is carried out to evaluate the pore size and porosity of structure, showing outstanding results that cause an entrapment efficiency of 57% for MSNPs-CS-DX. Furthermore, the findings demonstrate the pH sensitivity of MSNPs-CS-DX on drug release kinetics. Notably, the CS-DX layer exhibits a significant enhancement in cell viability of human umbilical vein endothelial cells (HUVEC) by approximately 24% within a 24 h timeframe compared to MSNPs lacking CS-DX.
摘要：
壳聚糖（CS）包覆的介孔二氧化硅纳米颗粒（MSNPs）被证明是用于药物递送目的的载体的合适候选物。然而,选择合适的含药物的复合物应用于MSNP-CS对于评估有效结合细胞活力的可能候选者更为重要。药物释放动力学，和动脉粥样硬化的预防。在这方面,本研究集中于设计用于药物递送目的的包衣MSNP-CS的合成和评估。MSNP涂覆有由CS和硫酸葡聚糖（MSNP-CS-DX）组成的聚电解质复合物（PEC），作为具有良好生物学特性的多功能药物载体。CS-DX应用于MSNP而不需要复杂的或多步骤的合成程序。瑞舒伐他汀,一种降胆固醇的药物，选择它的治疗相关性。此外,CS-DX被发现相对阻碍巨噬细胞对低密度脂蛋白（LDLs）的摄取，增强其潜在的治疗效用。FTIR图案,FESEM，和TEM图像证明MSNP-CS-DX形成。DLS测量表明，MSNP的平均粒径为110nm，CS和DX层的组合厚度范围为10至15nm。进行BET测试以评估结构的孔径和孔隙率，显示出优异的结果，导致MSNP-CS-DX的捕获效率为57％。此外，研究结果证明了MSNPs-CS-DX对药物释放动力学的pH敏感性。值得注意的是,与缺乏CS-DX的MSNP相比，CS-DX层在24小时内显示人脐静脉内皮细胞（HUVEC）的细胞活力显着提高约24％。
